Intelligent surgical targeting

FluoGuide provides solutions for maximizing surgical outcome through intelligent targeting. FluoGuide’s first product, FG001, improves precision in cancer surgery by lighting up the cancer and its invasive growth into the surrounding tissue. The FluoGuide products is expected to reduce the suffering of patients and increase the likelihood of cure. They can also reduce costs for the health care system and thus benefit society. FluoGuide focuses on demonstrating the effect of FG001 in patients by conducting a human proof-of-concept clinical trial.

See video

FG001 - a unique innovation

FG001, FluoGuide’s first product, lights up the cancer and its invasive growth into the surrounding tissue. FG001 is made of a cancer targeting molecule linked to a fluorophore. The targeting molecules bind to the urokinase-type plasminogen activator receptor (“uPAR”). uPAR is extensively expressed by cancer cells and FluoGuide utilizes this fact in the development of FG001. It is currently prepared for a proof-of-concept clinical study.

More information